Company Overview of N-of-One, Inc.
N-of-One, Inc., a molecular decision support company, provides clinicians with interpretation of molecular test results. It provides disease-specific biological relevance, clinical evidence, associated therapies, and references. The company also interprets next generation sequencing (NGS) of solid and hematological tumors, circulating tumor cells and DNA, copy number analysis, and immunohistochemistry. In addition, it offers PrecisionInsights, a clinical interpretation report for 15-20 gene NGS panels, delivering concise clinical and scientific evidence for each biomarker in the context of the cancer sub type and a list of therapeutic options; and TRIALMATCH, a patient-specific clinical tria...
430 Bedford Street
Lexington, MA 02420
Founded in 2007
Key Executives for N-of-One, Inc.
Chairman and Chief Executive Officer
Founder, President, Chief Medical Officer and Director
Chief Financial Officer and Director
Vice President of Operations
Vice President, Secretary and General Counsel
Compensation as of Fiscal Year 2016.
N-of-One, Inc. Key Developments
Philips Teams Up with N-Of-One to Speed Up Clinical Interpretation of Cancer Genomics
Nov 11 16
Royal Philips and N-of-One, Inc. announced they are teaming up to enhance the capabilities of Philips' IntelliSpace Genomics solution. The two companies will collaborate on the clinical analysis, annotation and interpretation of oncology cases processed through Philips' new precision medicine solution for oncology. This healthcare informatics solution integrates genomic information with full patient context to empower clinicians with precision diagnostics and therapeutics, to enable them to measure the success of precision healthcare programs. Profiling tumors using genomic information is critical for complex cancer cases, yet challenges remain in rapidly and accurately interpreting genomic findings in the context of a patient's condition. While most cancer patients have thousands of gene variants and mutations, only a small number actually drive the individual's specific cancer or may have actionable therapeutic implications for a particular patient.
Med Fusion Selects N-Of-One to Provide Integrated Interpretation for Med Fusion’S New Hematologic Neoplasm Profiles
Nov 8 16
N-of-One, Inc. announced that med fusion has selected N-of-One to provide integrated interpretation of med fusion’s new HemeSEQ™ profiles for AML, CLL, DLBCL and MPN diseases. MDS and Myeloid profiles are in development and will be made available later in 2016. Financial terms of the agreement are not disclosed. med fusion’s HemeSEQ profiles help physicians rapidly diagnose, predict the course of disease progression and identify relevant clinical trial and treatment options for patients living with hematologic diseases. The HemeSEQ profiles expand med fusion’s hematological menu to nearly 100 tests by incorporating next generation sequencing (NGS) technology to provide physicians with an understanding of the molecular basis of the disease – an important component emphasized by the latest World Health Organization (WHO) recommendations to improve care of patients with hematologic neoplasms - without extending turnaround time or increasing specimen requirements. The cumulative findings are delivered via an integrated report that includes cytogenetic abnormalities and molecular mutations identified and matched to relevant clinical trial and therapy options for each patient utilizing N-of-One’s case analysis and proprietary knowledgebase and med fusion’s genetic analysts.
Inivata and N-of-One, Inc. Partner to Provide Personalized Genomic Interpretation and Clinical Trial Matching for Cancer Patients
Nov 3 16
Inivata and N-of-One, Inc. announced a new partnership to support analysis of patient cases for Inivata's InVision® liquid biopsy product line. This partnership will enable the delivery of clear, easy to interpret patient reports, providing physicians with a wealth of genomic information at their fingertips. Inivata's approach to ctDNA analysis delivers sensitivity across a broad panel of clinically relevant genomic alterations. The Next-Generation Sequencing-based method utilizes eTAm-Seq(TM), a proprietary amplification process, prior to sequencing and advanced analytical methods that enables the separation of true cancer mutations from background noise. The collaboration with N-of-One will provide each physician with an individualized liquid biopsy report based on their cancer patient's genomic signature. N-of-One's oncologists and Ph.D. scientists will also provide the analysis needed to assess current treatments, analyze potential novel mutations and allow the oncologists to make more informed decisions for treatment strategies. N-of-One will support Inivata's liquid biopsy assay by providing oncologists and pathologists with the most relevant oncology treatment options through the analysis of each patient's unique molecular profile. The N-of-One solution will integrate the interpretation of multiple molecular tests on a patient to provide a comprehensive view of the cancer and, leveraging N-of-One's proprietary database, will identify individualized treatment options, including clinical trials for consideration by the oncologist. N-of-One's experience in oncology, and specifically liquid biopsies, makes them capable of interpreting the Inivata liquid biopsy test.
Similar Private Companies By Industry
Recent Private Companies Transactions
January 18, 2017